Inso Biosciences

Biotechnology ResearchNew York, United States2-10 Employees

Inso Bio is simplifying DNA sample workflows to unlock broader access to genomic medicine and research.

While DNA sequencing has advanced rapidly, front-end sample preparation has stagnated on decades-old bead- and column-based affinity binding technologies. These approaches often require complex, expensive automation systems and constrain the ultimate scale and accessibility of genomic applications.

Inso Bio has developed the world's first solid-phase DNA capture platform using microfluidic technologies invented at Cornell University. Rather than relying on chemical affinity binding, our micropillar architecture physically entangles DNA — similar to hair on a brush — enabling integrated extraction and enzymatic processing on-chip.

By overcoming limitations of traditional binding-based methods, our platform is designed to enable more affordable automation with minimal setup, faster turnaround, improved efficiency, preservation of long DNA fragments, and built-in multiomic capabilities.

Together, we are working toward a future where sample-to-answer genomic workflows can be completed at the push of a button.

Reach out to learn more.

Sign up for free to view info

Email Format Employee directory